首页 > 最新文献

Journal of Ayurveda and Integrative Medicine最新文献

英文 中文
Characterization of lead sulfide obtained from Naga Bhasma 从 Naga Bhasma 中提取的硫化铅的特征
IF 2.4 Q3 INTEGRATIVE & COMPLEMENTARY MEDICINE Pub Date : 2024-03-01 DOI: 10.1016/j.jaim.2023.100864
Manoj Kumar Dash , Namrata Joshi , Laxmikant Dwivedi , Vd Sushil Dubey , Kamal Nayan Dwivedi

Background

Lead sulfide nanoparticles were manufactured from lead oxide using a procedure described in the Ayurveda formulary of India, which involved using a quantum of the heat of up to 60 puta, which is officially known as the Shasti puta Naga Bhasma.

Objective

The study shows sulfurization of nanoparticles significantly decreased their toxicity due to the lower solubility.

Materials and Methods

The present work used the arsenic sulfide media and traditional puta for processing and the characterization of the same has been conducted. Different analytical techniques like X-ray diffraction (XRD), scanning electron microscopy (SEM), energy-dispersive X-Ray (EDX) spectroscopy, Fourier transform infrared spectroscopy (FTIR), and thermo-gravimetry analysis (TGA) were used.The study shows sulfurization of nanoparticles significantly decreased their toxicity due to the lower solubility. Materials and Methods: The present work used the arsenic sulfide media and traditional puta for Naga bhasma processing and the characterization of the same has been conducted. Different analytical techniques like X-ray diffraction (XRD), scanning electron microscopy (SEM), energy-dispersive X-Ray (EDX) spectroscopy, Fourier transform infrared spectroscopy (FTIR), and thermo-gravimetry analysis (TGA) were used.

Results

Powder x-ray diffraction, scanning electron microscopy, Fourier transform infrared spectroscopy, Thermogravimetric analysis, and differential thermal analysis all showed that the produced nanoparticles are lead sulfide nanoparticles with a particle size of an average of 84.60 and the crystalline average size of 69.06 nm.

Conclusion

The rounded, rod, oval, cubic, and circular morphology of the produced lead sulfide nanoparticles can be seen in the SEM image. The stretching and bending functional groups in the sample were alkanes, alkenes, aromatic hydrocarbons, aromatic hydrocarbons, carboxylic acids, alkyl carboxylic acids, alkyl alpha, beta-unsaturated, aldehydes, ketones, carboxylic acid, aliphatic amines, primary amines, secondary amines, alkyl halides, alkyl halides are studied through the FTIR spectrum.

背景使用印度阿育吠陀配方中描述的程序从氧化铅中制造出硫化铅纳米粒子,该程序涉及使用高达 60 puta 的热量,正式名称为 Shasti puta Naga Bhasma.Objective研究表明,由于溶解度较低,纳米粒子的硫化可显著降低其毒性。使用了不同的分析技术,如 X 射线衍射 (XRD)、扫描电子显微镜 (SEM)、能量色散 X 射线 (EDX) 光谱、傅立叶变换红外光谱 (FTIR) 和热重分析 (TGA)。材料和方法:本研究使用硫化砷介质和传统的 puta 来加工 Naga bhasma,并对其进行了表征。使用了不同的分析技术,如 X 射线衍射(XRD)、扫描电子显微镜(SEM)、能量色散 X 射线(EDX)光谱、傅立叶变换红外光谱(FTIR)和热重分析(TGA)。结果粉末 X 射线衍射、扫描电子显微镜、傅立叶变换红外光谱、热重分析和差热分析均表明所制备的纳米颗粒为硫化铅纳米颗粒,其平均粒径为 84.60 纳米,结晶平均粒径为 69.06 纳米。通过傅立叶变换红外光谱研究了样品中的伸展和弯曲官能团,包括烷、烯、芳香烃、芳香烃、羧酸、烷基羧酸、烷基α、β-不饱和、醛、酮、羧酸、脂肪族胺、伯胺、仲胺、烷基卤化物、烷基卤化物。
{"title":"Characterization of lead sulfide obtained from Naga Bhasma","authors":"Manoj Kumar Dash ,&nbsp;Namrata Joshi ,&nbsp;Laxmikant Dwivedi ,&nbsp;Vd Sushil Dubey ,&nbsp;Kamal Nayan Dwivedi","doi":"10.1016/j.jaim.2023.100864","DOIUrl":"https://doi.org/10.1016/j.jaim.2023.100864","url":null,"abstract":"<div><h3>Background</h3><p>Lead sulfide nanoparticles were manufactured from lead oxide using a procedure described in the Ayurveda formulary of India, which involved using a quantum of the heat of up to 60 puta, which is officially known as the <em>Shasti puta Naga Bhasma</em>.</p></div><div><h3>Objective</h3><p>The study shows sulfurization of nanoparticles significantly decreased their toxicity due to the lower solubility.</p></div><div><h3>Materials and Methods</h3><p>The present work used the arsenic sulfide media and traditional puta for processing and the characterization of the same has been conducted. Different analytical techniques like X-ray diffraction (XRD), scanning electron microscopy (SEM), energy-dispersive X-Ray (EDX) spectroscopy, Fourier transform infrared spectroscopy (FTIR), and thermo-gravimetry analysis (TGA) were used.The study shows sulfurization of nanoparticles significantly decreased their toxicity due to the lower solubility. Materials and Methods: The present work used the arsenic sulfide media and traditional puta for Naga bhasma processing and the characterization of the same has been conducted. Different analytical techniques like X-ray diffraction (XRD), scanning electron microscopy (SEM), energy-dispersive X-Ray (EDX) spectroscopy, Fourier transform infrared spectroscopy (FTIR), and thermo-gravimetry analysis (TGA) were used.</p></div><div><h3>Results</h3><p>Powder x-ray diffraction, scanning electron microscopy, Fourier transform infrared spectroscopy, Thermogravimetric analysis, and differential thermal analysis all showed that the produced nanoparticles are lead sulfide nanoparticles with a particle size of an average of 84.60 and the crystalline average size of 69.06 nm.</p></div><div><h3>Conclusion</h3><p>The rounded, rod, oval, cubic, and circular morphology of the produced lead sulfide nanoparticles can be seen in the SEM image. The stretching and bending functional groups in the sample were alkanes, alkenes, aromatic hydrocarbons, aromatic hydrocarbons, carboxylic acids, alkyl carboxylic acids, alkyl alpha, beta-unsaturated, aldehydes, ketones, carboxylic acid, aliphatic amines, primary amines, secondary amines, alkyl halides, alkyl halides are studied through the FTIR spectrum.</p></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"15 2","pages":"Article 100864"},"PeriodicalIF":2.4,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S097594762300181X/pdfft?md5=1b9111afc3c7d85e4e72044f5ecb67d0&pid=1-s2.0-S097594762300181X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140195809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An integrative approach for management of post-traumatic dorsal foot wounds - A case report 治疗创伤后足背伤口的综合方法 - 病例报告
IF 2.4 Q3 INTEGRATIVE & COMPLEMENTARY MEDICINE Pub Date : 2024-03-01 DOI: 10.1016/j.jaim.2024.100905
Rahul Sherkhane , Shruti Singh , Aadithyaraj K T , Anil Kumar , Ashish Sharma , Shiv Ji Gupta

Crush injuries to the foot have become increasingly prevalent in contemporary settings, primarily arising from incidents such as the impact of large objects falling onto the foot or involvement in traffic accidents. The complexity of treating these injuries is compounded by the intricate anatomy of the foot. In specific scenarios, the implementation of an integrated management approach could prove advantageous.

In this report, we depict the case of a 23-year-old male who visited the Shalya OPD with a wound on his left foot caused by trauma. The wound covered the medial portion of the foot, involving the dorsal area, and measured roughly 20 cm by 9 cm and was unable to walk. We successfully managed the case by adopting an integrative approach. The Ayurvedic treatment included Panchavalkala kashaya for wound irrigation, as well as oral administration of Amalaki rasayana, Triphala guggulu, Shatavari churna and Ashwagandha churna. Jatyadi taila was topically applied. For the first seven days, in addition to these ayurvedic medications, we also employed analgesics and antibiotics to treat infection and pain. To accomplish early closure, we employed a split-thickness skin graft after sufficient granulation tissue had appeared.

The wound was completely healed within three months and the patient was able to walk freely without any support. The combined approach yielded a promising result in this case.

足部挤压伤在现代环境中越来越普遍,主要是由于大型物体坠落到足部或卷入交通事故等事件造成的。由于足部解剖结构复杂,治疗这些损伤的复杂性也随之增加。在本报告中,我们描述了这样一个病例:一名 23 岁的男性因外伤导致左脚受伤而到 Shalya 手术室就诊。伤口覆盖足部内侧,涉及足背区域,面积约为 20 厘米乘 9 厘米,无法行走。我们采用综合方法成功地处理了这个病例。阿育吠陀疗法包括用于伤口灌洗的 Panchavalkala kashaya,以及口服 Amalaki rasayana、Triphala guggulu、Shatavari churna 和 Ashwagandha churna。局部使用 Jatyadi taila。在最初的七天里,除了这些阿育吠陀药物外,我们还使用了镇痛剂和抗生素来治疗感染和疼痛。为了实现早期闭合,我们在出现足够的肉芽组织后采用了分层厚皮移植术。伤口在三个月内完全愈合,患者可以在没有任何支撑的情况下自由行走。在这个病例中,综合方法取得了良好的效果。
{"title":"An integrative approach for management of post-traumatic dorsal foot wounds - A case report","authors":"Rahul Sherkhane ,&nbsp;Shruti Singh ,&nbsp;Aadithyaraj K T ,&nbsp;Anil Kumar ,&nbsp;Ashish Sharma ,&nbsp;Shiv Ji Gupta","doi":"10.1016/j.jaim.2024.100905","DOIUrl":"https://doi.org/10.1016/j.jaim.2024.100905","url":null,"abstract":"<div><p>Crush injuries to the foot have become increasingly prevalent in contemporary settings, primarily arising from incidents such as the impact of large objects falling onto the foot or involvement in traffic accidents. The complexity of treating these injuries is compounded by the intricate anatomy of the foot. In specific scenarios, the implementation of an integrated management approach could prove advantageous.</p><p>In this report, we depict the case of a 23-year-old male who visited the Shalya OPD with a wound on his left foot caused by trauma. The wound covered the medial portion of the foot, involving the dorsal area, and measured roughly 20 cm by 9 cm and was unable to walk. We successfully managed the case by adopting an integrative approach. The Ayurvedic treatment included <em>Panchavalkala kashaya</em> for wound irrigation, as well as oral administration of <em>Amalaki rasayana, Triphala guggulu</em>, <em>Shatavari churna</em> and <em>Ashwagandha churna</em>. <em>Jatyadi taila</em> was topically applied. For the first seven days, in addition to these ayurvedic medications, we also employed analgesics and antibiotics to treat infection and pain. To accomplish early closure, we employed a split-thickness skin graft after sufficient granulation tissue had appeared.</p><p>The wound was completely healed within three months and the patient was able to walk freely without any support. The combined approach yielded a promising result in this case.</p></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"15 2","pages":"Article 100905"},"PeriodicalIF":2.4,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0975947624000202/pdfft?md5=e9598fd3f6bb8719840d055f598b91ba&pid=1-s2.0-S0975947624000202-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140345091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A critical review of the book ‘Arbuda chikitsa- Ayurvedathile veritta vazhikal’ by Dr. P. B. Susheela Saji 对 P. B. Susheela Saji 博士所著《Arbuda chikitsa- Ayurvedathile veritta vazhikal》一书的批判性评论
IF 2.4 Q3 INTEGRATIVE & COMPLEMENTARY MEDICINE Pub Date : 2024-03-01 DOI: 10.1016/j.jaim.2024.100894
C.K. Saniya, Parvathy G. Nair, P.S. Aswani, A.P. Karthika
{"title":"A critical review of the book ‘Arbuda chikitsa- Ayurvedathile veritta vazhikal’ by Dr. P. B. Susheela Saji","authors":"C.K. Saniya,&nbsp;Parvathy G. Nair,&nbsp;P.S. Aswani,&nbsp;A.P. Karthika","doi":"10.1016/j.jaim.2024.100894","DOIUrl":"https://doi.org/10.1016/j.jaim.2024.100894","url":null,"abstract":"","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"15 2","pages":"Article 100894"},"PeriodicalIF":2.4,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0975947624000093/pdfft?md5=0f3f7bf443a7f328629277d74b1a488a&pid=1-s2.0-S0975947624000093-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140296942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Yoga Nidra for hypertension: A systematic review and meta-analysis 治疗高血压的瑜伽 Nidra:系统回顾与荟萃分析
IF 2.4 Q3 INTEGRATIVE & COMPLEMENTARY MEDICINE Pub Date : 2024-03-01 DOI: 10.1016/j.jaim.2023.100882
Navdeep Ahuja , Praag Bhardwaj , Monika Pathania , Dilasha Sethi , Arjun Kumar , Ashwin Parchani , Akshita Chandel , Aashish Phadke
<div><h3>Background</h3><p>Hypertension is a prevalent chronic condition that affects a substantial proportion of the world's population. Medications are commonly prescribed for hypertension management, but non-pharmacological interventions like yoga are gaining popularity.</p></div><div><h3>Objective</h3><p>The purpose of this systematic review and meta-analysis is to assess the efficacy of Yoga Nidra (YN) for the management of hypertension.</p></div><div><h3>Methods</h3><p>A systematic review and meta-analysis of clinical trials, i.e., non-randomized and randomized controlled trials (RCTs) was conducted to investigate the effects of YN on hypertension. PubMed, the Cochrane Library, SCOPUS, and EBSCO were searched for relevant studies published up to September 2022. The quality of the included studies was assessed using the Cochrane risk of bias tool. The primary outcome measure was the change in systolic blood pressure (SBP) and diastolic blood pressure (DBP) after YN intervention, analyzed as weighted mean difference (WMD), in comparison to control groups. The random-effects model was used for the meta-analysis. Risk of bias was assessed for RCTs and non-RCTs using Cochrane's RoB-2 and ROBINS-I tools, respectively.</p></div><div><h3>Results</h3><p>Five RCTs and three Non-RCTs involving a total of 482 participants (239 for YN vs 243 for controls) were included in this review. The meta-analysis indicated that YN significantly reduced SBP (WMD = 12.03 mm Hg, 95% CI [7.12, 16.93], <em>Z</em> = 4.80, <em>p</em> < 0.00001) and DBP (WMD = 6.32 mm Hg, 95% CI [3.53, 9.12], <em>Z</em> = 4.43, <em>p</em> < 0.00001) compared to control groups. The overall risk of bias for the three RCTs was high, whereas for the five non-RCTs, one had an overall moderate risk while the other four had an overall serious risk of bias.</p></div><div><h3>Discussion</h3><p>This systematic review and meta-analysis provides evidence supporting the efficacy of YN as a complementary therapy for hypertension management. YN is a safe, cost-effective, and easily accessible intervention that primarily relies on interoception and induces a deep relaxation response in practitioners, aiding them in coping with various components of high blood pressure, such as stress, vascular inflammation, peripheral vascular resistance, etc. Our understanding of the mechanisms of YN is constantly evolving, and there is a need for further research to fully explore and appreciate the significance of this ancient science and its potential efficacy on BP. Considering the results and the multifactorial role of YN, it can act as a safe and reliable adjuvant therapy to complement the pharmacological treatment of hypertension. However, further studies with larger sample sizes, longer follow-up periods, and homogenous populations are warranted.</p></div><div><h3>Conclusion</h3><p>This meta-analysis suggests that YN is effective in reducing SBP and DBP, particularly in individuals with hypertension. The re
背景高血压是一种普遍存在的慢性疾病,影响着世界上很大一部分人口。本系统综述和荟萃分析的目的是评估瑜伽静坐(Yoga Nidra,YN)对高血压的疗效。方法对临床试验,即非随机和随机对照试验(RCTs)进行了系统综述和荟萃分析,以研究 YN 对高血压的影响。研究人员检索了 PubMed、Cochrane 图书馆、SCOPUS 和 EBSCO 上截至 2022 年 9 月发表的相关研究。使用 Cochrane 偏倚风险工具对纳入研究的质量进行了评估。主要结果指标是 YN 干预后收缩压(SBP)和舒张压(DBP)的变化,以加权平均差(WMD)分析,并与对照组进行比较。荟萃分析采用随机效应模型。采用 Cochrane 的 RoB-2 和 ROBINS-I 工具分别评估了 RCT 和非 RCT 的偏倚风险。荟萃分析表明,与对照组相比,YN 能显著降低 SBP(WMD = 12.03 mm Hg,95% CI [7.12,16.93],Z = 4.80,p < 0.00001)和 DBP(WMD = 6.32 mm Hg,95% CI [3.53,9.12],Z = 4.43,p < 0.00001)。三项研究性试验的总体偏倚风险较高,而五项非研究性试验中,一项研究性试验的总体偏倚风险为中等,其他四项研究性试验的总体偏倚风险为严重。YN是一种安全、具有成本效益且容易获得的干预方法,主要依赖于互感,能诱导练习者产生深度放松反应,帮助他们应对高血压的各种因素,如压力、血管炎症、外周血管阻力等。我们对 YN 机制的认识在不断发展,需要进一步研究,以充分探索和认识这一古老科学的意义及其对血压的潜在疗效。考虑到上述研究结果和云南白药的多因素作用,它可以作为一种安全可靠的辅助疗法,补充高血压的药物治疗。结论这项荟萃分析表明,YN 能有效降低 SBP 和 DBP,尤其是对高血压患者。这些结果凸显了 YN 作为高血压管理辅助疗法的潜力。医疗服务提供者可以考虑向高血压患者推荐 YN,作为药物治疗的辅助疗法。还需要进一步研究,以确定最适合高血压管理的标准化最佳YN形式和持续时间。
{"title":"Yoga Nidra for hypertension: A systematic review and meta-analysis","authors":"Navdeep Ahuja ,&nbsp;Praag Bhardwaj ,&nbsp;Monika Pathania ,&nbsp;Dilasha Sethi ,&nbsp;Arjun Kumar ,&nbsp;Ashwin Parchani ,&nbsp;Akshita Chandel ,&nbsp;Aashish Phadke","doi":"10.1016/j.jaim.2023.100882","DOIUrl":"https://doi.org/10.1016/j.jaim.2023.100882","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;p&gt;Hypertension is a prevalent chronic condition that affects a substantial proportion of the world's population. Medications are commonly prescribed for hypertension management, but non-pharmacological interventions like yoga are gaining popularity.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;p&gt;The purpose of this systematic review and meta-analysis is to assess the efficacy of Yoga Nidra (YN) for the management of hypertension.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;p&gt;A systematic review and meta-analysis of clinical trials, i.e., non-randomized and randomized controlled trials (RCTs) was conducted to investigate the effects of YN on hypertension. PubMed, the Cochrane Library, SCOPUS, and EBSCO were searched for relevant studies published up to September 2022. The quality of the included studies was assessed using the Cochrane risk of bias tool. The primary outcome measure was the change in systolic blood pressure (SBP) and diastolic blood pressure (DBP) after YN intervention, analyzed as weighted mean difference (WMD), in comparison to control groups. The random-effects model was used for the meta-analysis. Risk of bias was assessed for RCTs and non-RCTs using Cochrane's RoB-2 and ROBINS-I tools, respectively.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;p&gt;Five RCTs and three Non-RCTs involving a total of 482 participants (239 for YN vs 243 for controls) were included in this review. The meta-analysis indicated that YN significantly reduced SBP (WMD = 12.03 mm Hg, 95% CI [7.12, 16.93], &lt;em&gt;Z&lt;/em&gt; = 4.80, &lt;em&gt;p&lt;/em&gt; &lt; 0.00001) and DBP (WMD = 6.32 mm Hg, 95% CI [3.53, 9.12], &lt;em&gt;Z&lt;/em&gt; = 4.43, &lt;em&gt;p&lt;/em&gt; &lt; 0.00001) compared to control groups. The overall risk of bias for the three RCTs was high, whereas for the five non-RCTs, one had an overall moderate risk while the other four had an overall serious risk of bias.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Discussion&lt;/h3&gt;&lt;p&gt;This systematic review and meta-analysis provides evidence supporting the efficacy of YN as a complementary therapy for hypertension management. YN is a safe, cost-effective, and easily accessible intervention that primarily relies on interoception and induces a deep relaxation response in practitioners, aiding them in coping with various components of high blood pressure, such as stress, vascular inflammation, peripheral vascular resistance, etc. Our understanding of the mechanisms of YN is constantly evolving, and there is a need for further research to fully explore and appreciate the significance of this ancient science and its potential efficacy on BP. Considering the results and the multifactorial role of YN, it can act as a safe and reliable adjuvant therapy to complement the pharmacological treatment of hypertension. However, further studies with larger sample sizes, longer follow-up periods, and homogenous populations are warranted.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;p&gt;This meta-analysis suggests that YN is effective in reducing SBP and DBP, particularly in individuals with hypertension. The re","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"15 2","pages":"Article 100882"},"PeriodicalIF":2.4,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0975947623001997/pdfft?md5=2b4d326872a62fe3d67d4288d868a146&pid=1-s2.0-S0975947623001997-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140122039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ayurvedic management of a refractory skin disease clinically diagnosed as Cutaneous Lichen Planus—A case report 临床诊断为皮肤扁平苔藓的难治性皮肤病的阿育吠陀疗法--病例报告
IF 2.4 Q3 INTEGRATIVE & COMPLEMENTARY MEDICINE Pub Date : 2024-03-01 DOI: 10.1016/j.jaim.2023.100884
Sushma Naranappa Salethoor , Shyamasundaran Kulangara , A.R. Aramya , Rammanohar Puthiyedath

This study reports the successful management of a recurrent, refractory skin disease diagnosed clinically as Cutaneous Lichen Planus (CLP) in a female patient with Ayurvedic treatment. A 42-year-old home maker from Coimbatore presented with blackish-red pigmented skin rashes and white streaks. Though mucous membranes were not affected, she did not respond to homoeopathic and biomedical treatment. The lesions were spread all over the body except for the face, scalp, axillary and genital region. In addition, she complained of dry skin, pain, and itching.

The condition was treated as Kapha-Pitta dominant Tridoshaja Kushta based on Ayurvedic clinical assessment. The patient recovered after one year of conservative Ayurvedic intervention. After six years, there was a relapse, and the patient was admitted for a full course of Ayurvedic treatment and recovered within six months. Ayurvedic interventions should be considered an option in refractory skin diseases like Cutaneous Lichen Planus.

本研究报告了一名女性患者通过阿育吠陀疗法成功治愈了临床诊断为皮肤扁平苔藓(CLP)的复发性难治性皮肤病。一名来自哥印拜陀的 42 岁家庭主妇出现了黑红色的色素性皮疹和白色条纹。虽然粘膜没有受到影响,但她对同种疗法和生物医学治疗没有反应。除面部、头皮、腋窝和生殖器区域外,皮损遍布全身。此外,她还抱怨皮肤干燥、疼痛和瘙痒。根据阿育吠陀临床评估,该病症被视为卡帕-皮塔主导型 Tridoshaja Kushta。经过一年的阿育吠陀保守治疗,患者痊愈了。六年后,该病复发,患者入院接受了完整的阿育吠陀治疗,并在六个月内痊愈。对于像皮肤扁平苔藓这样的难治性皮肤病,阿育吠陀疗法干预应被视为一种选择。
{"title":"Ayurvedic management of a refractory skin disease clinically diagnosed as Cutaneous Lichen Planus—A case report","authors":"Sushma Naranappa Salethoor ,&nbsp;Shyamasundaran Kulangara ,&nbsp;A.R. Aramya ,&nbsp;Rammanohar Puthiyedath","doi":"10.1016/j.jaim.2023.100884","DOIUrl":"https://doi.org/10.1016/j.jaim.2023.100884","url":null,"abstract":"<div><p>This study reports the successful management of a recurrent, refractory skin disease diagnosed clinically as Cutaneous Lichen Planus (CLP) in a female patient with <em>Ayurvedic</em> treatment. A 42-year-old home maker from <em>Coimbatore</em> presented with blackish-red pigmented skin rashes and white streaks. Though mucous membranes were not affected, she did not respond to homoeopathic and biomedical treatment. The lesions were spread all over the body except for the face, scalp, axillary and genital region. In addition, she complained of dry skin, pain, and itching.</p><p>The condition was treated as <em>Kapha-Pitta</em> dominant <em>Tridoshaja Kushta</em> based on <em>Ayurvedic</em> clinical assessment. The patient recovered after one year of conservative <em>Ayurvedic</em> intervention. After six years, there was a relapse, and the patient was admitted for a full course of <em>Ayurvedic</em> treatment and recovered within six months. <em>Ayurvedic</em> interventions should be considered an option in refractory skin diseases like Cutaneous Lichen Planus.</p></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"15 2","pages":"Article 100884"},"PeriodicalIF":2.4,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0975947623002012/pdfft?md5=7da889aa6a03451675ed65b6ccf803a8&pid=1-s2.0-S0975947623002012-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140181142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rapid improvement of oculomotor nerve function with ayurvedic treatment in traumatic diplopia - A case report 外伤性复视患者经阿育吠陀治疗后眼球运动神经功能迅速改善--病例报告
IF 2.4 Q3 INTEGRATIVE & COMPLEMENTARY MEDICINE Pub Date : 2024-03-01 DOI: 10.1016/j.jaim.2024.100889
K. Shanti , G. Gopinathan

Diplopia or double vision has many aetiologies and often presents to the ophthalmologist. The causes of diplopia may be ocular or neurogenic in origin. Any trauma to the eyes in the form of blow-out fractures causes diplopia by damaging the third nerve. The management by the practitioners of contemporary science depends upon the extent of the nerve or muscle injury. Entrapment of muscles requires surgical intervention, whereas others are managed conservatively. The recovery rate is the least for diplopia of traumatic origin.

A 50-year-old male who sought Ayurvedic treatment for diplopia in the last three months was diagnosed with partial third nerve palsy after a fracture of the left orbit. He underwent Ayurvedic therapy in the form of internal medicines such as Danadanayanadi kashaya, Ksheerabala 101, Vaishwanara churna, and external treatments such as Pratimarsha Nasya, Siro abhyanga, and Tarpana.

At the end of 2 months of Ayurvedic treatment, the patient completely recovered from diplopia.

Ayurvedic treatment effectively resolved diplopia in a short time. Patients can benefit from the same if treated promptly in the early stage itself. However, more extensive studies with larger samples will yield more data to prove the potential of Ayurveda in such cases.

复视或重影有多种病因,通常会出现在眼科医生面前。复视的病因可能是眼源性的,也可能是神经源性的。任何眼外伤(如爆裂性骨折)都会损伤第三神经,从而导致复视。当代科学从业者的处理方法取决于神经或肌肉损伤的程度。肌肉损伤需要手术治疗,而其他损伤则需要保守治疗。一名 50 岁的男性在过去三个月中因复视寻求阿育吠陀疗法治疗,被诊断为左眼眶骨折后部分第三神经麻痹。他接受了阿育吠陀疗法,内服药包括 Danadanayanadi kashaya、Ksheerabala 101、Vaishwanara churna,外用药包括 Pratimarsha Nasya、Siro abhyanga 和 Tarpana。阿育吠陀疗法能在短时间内有效解决复视问题,如果能在早期及时治疗,患者也能从中受益。然而,更广泛的研究和更大的样本将产生更多的数据来证明阿育吠陀在此类病例中的潜力。
{"title":"Rapid improvement of oculomotor nerve function with ayurvedic treatment in traumatic diplopia - A case report","authors":"K. Shanti ,&nbsp;G. Gopinathan","doi":"10.1016/j.jaim.2024.100889","DOIUrl":"https://doi.org/10.1016/j.jaim.2024.100889","url":null,"abstract":"<div><p>Diplopia or double vision has many aetiologies and often presents to the ophthalmologist. The causes of diplopia may be ocular or neurogenic in origin. Any trauma to the eyes in the form of blow-out fractures causes diplopia by damaging the third nerve. The management by the practitioners of contemporary science depends upon the extent of the nerve or muscle injury. Entrapment of muscles requires surgical intervention, whereas others are managed conservatively. The recovery rate is the least for diplopia of traumatic origin.</p><p>A 50-year-old male who sought Ayurvedic treatment for diplopia in the last three months was diagnosed with partial third nerve palsy after a fracture of the left orbit. He underwent Ayurvedic therapy in the form of internal medicines such as <em>Danadanayanadi kashaya, Ksheerabala 101, Vaishwanara churna,</em> and external treatments such as <em>Pratimarsha Nasya, Siro abhyanga, and Tarpana</em>.</p><p>At the end of 2 months of Ayurvedic treatment, the patient completely recovered from diplopia.</p><p>Ayurvedic treatment effectively resolved diplopia in a short time. Patients can benefit from the same if treated promptly in the early stage itself. However, more extensive studies with larger samples will yield more data to prove the potential of Ayurveda in such cases.</p></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"15 2","pages":"Article 100889"},"PeriodicalIF":2.4,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0975947624000044/pdfft?md5=ca6829186210d635b2932abb7caa17b6&pid=1-s2.0-S0975947624000044-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140163992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of whole system ayurveda management protocol in major depressive disorder- A randomized controlled clinical trial 阿育吠陀全系统管理方案对重度抑郁症的疗效--随机对照临床试验
IF 2.4 Q3 INTEGRATIVE & COMPLEMENTARY MEDICINE Pub Date : 2024-03-01 DOI: 10.1016/j.jaim.2024.100896
Anjali Punia , Sameeran Chate , Basavaraj R. Tubaki , Nagula Himaja

Background

Major Depressive Disorder (MDD) is one of the common depressive disorder. MDD has high comorbidity and has greater implications on quality of life. Whole system Ayurveda management protocol (WSAP) is explored for it's possible role in management of MDD.

Objective

To evaluate the efficacy of Whole system Ayurveda management protocol on Major Depressive Disorder.

Material and Methods

Study was a randomized controlled trial. Total 50 patients of MDD meeting the DSM V criteria, age group 20–70 years of either sex participated in the study. They were randomly divided into two groups, control group received Escitalopram 10 mg twice a day and Ayurveda group was on WSAP. Interventions were for 60 days. Assessments were done through various clinical parameters like Hamilton Depression Rating Scale (HDRS), Hamilton Anxiety Rating Scale (HARS), Brief psychiatric rating scale (BPRS), Pittsburgh Sleep Quality Index (PSQI), WHO Quality of Life- BREF (WHOQOL-BREF), Clinical Global Improvement scale (CGI), UKU Side effect scale. Assessments during intervention was on every 15th day.

Results

Study showed that Ayurveda group produced significant outcome improvement compared to control group in HDRS (p = 0.01), HARS (p = 0.03), PSQI (p = 0.03), WHOQOL-Bref (p < 0.001) and UKU side effect scale (p = 0.02). Both the group showed improvements in all the parameters except in WHOQOL-Bref where Ayurveda group only showed improvements (p < 0.001). Effect size showed large effect in WHOQOL-Bref. Mild side effects were reported in control group and none in Ayurveda group.

Conclusion

WSAP was effective in management of MDD and had better side effect profile. Further studies needed.

背景重度抑郁症(MDD)是常见的抑郁症之一。重度抑郁症的合并症较高,对生活质量的影响也较大。研究探索了全系统阿育吠陀管理方案(WSAP)在管理 MDD 方面可能发挥的作用。目的 评估全系统阿育吠陀管理方案对重度抑郁症的疗效。共有 50 名符合 DSM V 标准、年龄在 20-70 岁之间的重度抑郁症患者参加了研究。他们被随机分为两组,对照组服用艾司西酞普兰 10 毫克,每天两次,阿育吠陀组服用 WSAP。干预期为 60 天。通过各种临床参数进行评估,如汉密尔顿抑郁评定量表(HDRS)、汉密尔顿焦虑评定量表(HARS)、简明精神病评定量表(BPRS)、匹兹堡睡眠质量指数(PSQI)、世界卫生组织生活质量标准(WHOQOL-BREF)、临床总体改善量表(CGI)、UKU副作用量表。研究结果表明,与对照组相比,阿育吠陀组在 HDRS(p = 0.01)、HARS(p = 0.03)、PSQI(p = 0.03)、WHOQOL-BREF(p < 0.001)和 UKU 副作用量表(p = 0.02)方面均有显著改善。除阿育吠陀组在 WHOQOL-Bref 方面有所改善(p < 0.001)外,两组在所有参数方面均有所改善。效应大小显示,WHOQOL-Bref 的效应较大。对照组有轻微的副作用,而阿育吠陀组没有副作用。需要进一步研究。
{"title":"Efficacy of whole system ayurveda management protocol in major depressive disorder- A randomized controlled clinical trial","authors":"Anjali Punia ,&nbsp;Sameeran Chate ,&nbsp;Basavaraj R. Tubaki ,&nbsp;Nagula Himaja","doi":"10.1016/j.jaim.2024.100896","DOIUrl":"https://doi.org/10.1016/j.jaim.2024.100896","url":null,"abstract":"<div><h3>Background</h3><p>Major Depressive Disorder (MDD) is one of the common depressive disorder. MDD has high comorbidity and has greater implications on quality of life. Whole system Ayurveda management protocol <em>(WSAP)</em> is explored for it's possible role in management of MDD.</p></div><div><h3>Objective</h3><p>To evaluate the efficacy of Whole system Ayurveda management protocol on Major Depressive Disorder.</p></div><div><h3>Material and Methods</h3><p>Study was a randomized controlled trial. Total 50 patients of MDD meeting the DSM V criteria, age group 20–70 years of either sex participated in the study. They were randomly divided into two groups, control group received Escitalopram 10 mg twice a day and Ayurveda group was on WSAP. Interventions were for 60 days. Assessments were done through various clinical parameters like Hamilton Depression Rating Scale (HDRS), Hamilton Anxiety Rating Scale (HARS), Brief psychiatric rating scale (BPRS), Pittsburgh Sleep Quality Index (PSQI), WHO Quality of Life- BREF (WHOQOL-BREF), Clinical Global Improvement scale (CGI), UKU Side effect scale. Assessments during intervention was on every 15th day.</p></div><div><h3>Results</h3><p>Study showed that Ayurveda group produced significant outcome improvement compared to control group in HDRS (p = 0.01), HARS (p = 0.03), PSQI (p = 0.03), WHOQOL-Bref (p &lt; 0.001) and UKU side effect scale (p = 0.02). Both the group showed improvements in all the parameters except in WHOQOL-Bref where Ayurveda group only showed improvements (p &lt; 0.001). Effect size showed large effect in WHOQOL-Bref. Mild side effects were reported in control group and none in Ayurveda group.</p></div><div><h3>Conclusion</h3><p><em>WSAP was</em> effective in management of MDD and had better side effect profile. Further studies needed.</p></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"15 2","pages":"Article 100896"},"PeriodicalIF":2.4,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0975947624000111/pdfft?md5=9930dc45b32d0009e6d09c91cfd6bccc&pid=1-s2.0-S0975947624000111-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140546322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunomodulatory effect of Unani polyherbal formulation - Tiryaq Wabai in mild to moderate COVID-19 patients – A randomized placebo-controlled clinical trial 乌纳尼多草药配方--Tiryaq Wabai 对轻中度 COVID-19 患者的免疫调节作用--随机安慰剂对照临床试验
IF 2.4 Q3 INTEGRATIVE & COMPLEMENTARY MEDICINE Pub Date : 2024-03-01 DOI: 10.1016/j.jaim.2024.100903
Ansul Kumar , Mohd Saif Khan , Zeya Ul Haque , Arpita Rai , Mohammad Fazil , Gulam Rabbani

Background

The pathogenesis of COVID-19 includes an integrated immune-inflammatory response. Modulation of host immune responses against the SARS-CoV-2 virus might be effective therapeutic management. Various Unani formulations have an immunomodulatory effect.

Objective

To explore the immunomodulatory effect and safety of Unani polyherbal drug (Tiryaq Wabai) in COVID-19 patients.

Materials and methods

The current study was a randomized placebo-controlled clinical trial that included 92 mild to moderate COVID-19 patients randomized into two groups. The Unani formulation Tiryaq Wabai (2 gm orally once a day) was used as an intervention for 45 days, while the control group received a placebo. Both groups received standard care treatment. The primary outcome was 50% increment in absolute lymphocyte count (ALC). The secondary outcome was 50% increment in mean lymphocyte percentage, CD4 cells, and CD8 cell count. The mean increase in all the above parameters has also been studied. Relevant statistical tests were used to analyze the effect.

Results

A statistically significant improvement in a 50% increase in ALC (p-value, 0.004), lymphocyte percentage (p-value, 0.056), CD4 (p-value, 0.005), and CD8 cell count (p-value, 0.050) was reported. Also, a significant improvement in the mean value of the lymphocyte percentage (p-value 0.0007), ALC (p-value 0.0022), CD4 cell count (p-value 0.0025), and CD8 cell count (p-value 0.0093) was observed after the treatment. One adverse event of mild grade was reported in the placebo group. The analysis of safety parameters (LFT and KFT) was normal for both groups.

Conclusion

In mild to moderate COVID-19 patients, Tiryaq Wabai effectively showed immunomodulatory activity by improving ALC count, lymphocyte percentage, CD4, and CD8 cell count.

背景 COVID-19 的发病机制包括综合免疫-炎症反应。调节宿主对 SARS-CoV-2 病毒的免疫反应可能是有效的治疗方法。材料和方法本研究是一项随机安慰剂对照临床试验,将 92 名轻度至中度 COVID-19 患者随机分为两组。干预组使用尤那尼配方 Tiryaq Wabai(每天口服一次,每次 2 克),为期 45 天;对照组使用安慰剂。两组均接受标准护理治疗。主要结果是绝对淋巴细胞计数(ALC)增加 50%。次要结果是平均淋巴细胞百分比、CD4 细胞和 CD8 细胞计数增加 50%。此外,还对上述所有参数的平均增幅进行了研究。结果报告显示,ALC(P 值,0.004)、淋巴细胞百分比(P 值,0.056)、CD4(P 值,0.005)和 CD8 细胞计数(P 值,0.050)增加 50% 有统计学意义。此外,治疗后还观察到淋巴细胞百分比(p 值 0.0007)、ALC(p 值 0.0022)、CD4 细胞计数(p 值 0.0025)和 CD8 细胞计数(p 值 0.0093)的平均值均有明显改善。安慰剂组报告了一起轻度不良事件。结论 在轻中度 COVID-19 患者中,Tiryaq Wabai 能有效改善 ALC 细胞计数、淋巴细胞百分比、CD4 和 CD8 细胞计数,从而显示出免疫调节活性。
{"title":"Immunomodulatory effect of Unani polyherbal formulation - Tiryaq Wabai in mild to moderate COVID-19 patients – A randomized placebo-controlled clinical trial","authors":"Ansul Kumar ,&nbsp;Mohd Saif Khan ,&nbsp;Zeya Ul Haque ,&nbsp;Arpita Rai ,&nbsp;Mohammad Fazil ,&nbsp;Gulam Rabbani","doi":"10.1016/j.jaim.2024.100903","DOIUrl":"https://doi.org/10.1016/j.jaim.2024.100903","url":null,"abstract":"<div><h3>Background</h3><p>The pathogenesis of COVID-19 includes an integrated immune-inflammatory response. Modulation of host immune responses against the SARS-CoV-2 virus might be effective therapeutic management. Various Unani formulations have an immunomodulatory effect.</p></div><div><h3>Objective</h3><p>To explore the immunomodulatory effect and safety of Unani polyherbal drug (<em>Tiryaq Wabai</em>) in COVID-19 patients.</p></div><div><h3>Materials and methods</h3><p>The current study was a randomized placebo-controlled clinical trial that included 92 mild to moderate COVID-19 patients randomized into two groups. The Unani formulation <em>Tiryaq Wabai</em> (2 gm orally once a day) was used as an intervention for 45 days, while the control group received a placebo. Both groups received standard care treatment. The primary outcome was 50% increment in absolute lymphocyte count (ALC). The secondary outcome was 50% increment in mean lymphocyte percentage, CD4 cells, and CD8 cell count. The mean increase in all the above parameters has also been studied. Relevant statistical tests were used to analyze the effect.</p></div><div><h3>Results</h3><p>A statistically significant improvement in a 50% increase in ALC (p-value, 0.004), lymphocyte percentage (p-value, 0.056), CD4 (p-value, 0.005), and CD8 cell count (p-value, 0.050) was reported. Also, a significant improvement in the mean value of the lymphocyte percentage (p-value 0.0007), ALC (p-value 0.0022), CD4 cell count (p-value 0.0025), and CD8 cell count (p-value 0.0093) was observed after the treatment. One adverse event of mild grade was reported in the placebo group. The analysis of safety parameters (LFT and KFT) was normal for both groups.</p></div><div><h3>Conclusion</h3><p>In mild to moderate COVID-19 patients, <em>Tiryaq Wabai</em> effectively showed immunomodulatory activity by improving ALC count, lymphocyte percentage, CD4, and CD8 cell count.</p></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"15 2","pages":"Article 100903"},"PeriodicalIF":2.4,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0975947624000184/pdfft?md5=8e7c984385b2056c4a79ca79734677e7&pid=1-s2.0-S0975947624000184-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140344488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to “A century of ‘The science of yoga’ (1921–2021): Revival, renewal and renaissance” [J. Ayurveda Integr. Med. 14 (2023) 100613] 瑜伽科学 "的一个世纪(1921-2021 年):复兴、更新与复兴"[J. Ayurveda Integr. Med. 14 (2023) 100613] 更正
IF 2.4 Q3 INTEGRATIVE & COMPLEMENTARY MEDICINE Pub Date : 2024-03-01 DOI: 10.1016/j.jaim.2024.100927
Ashok D.B. Vaidya, Rama Vaidya
{"title":"Corrigendum to “A century of ‘The science of yoga’ (1921–2021): Revival, renewal and renaissance” [J. Ayurveda Integr. Med. 14 (2023) 100613]","authors":"Ashok D.B. Vaidya,&nbsp;Rama Vaidya","doi":"10.1016/j.jaim.2024.100927","DOIUrl":"https://doi.org/10.1016/j.jaim.2024.100927","url":null,"abstract":"","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"15 2","pages":"Article 100927"},"PeriodicalIF":2.4,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0975947624000421/pdfft?md5=2cecf69e74ea319216052ea0346e4fd1&pid=1-s2.0-S0975947624000421-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140647455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Duration of fermentation affects microbiome composition and biological activity of an Indian traditional formulation – Panchagavya 发酵时间影响印度传统配方 - Panchagavya 的微生物群组成和生物活性
IF 2.4 Q3 INTEGRATIVE & COMPLEMENTARY MEDICINE Pub Date : 2024-03-01 DOI: 10.1016/j.jaim.2023.100880
Gemini Gajera , Snehal Funde , Hanmanthrao Palep , Vijay Kothari

Objective

This study aimed at investigating whether the duration of fermenting Panchagavya (PG) preparation in copper vessel affects its biological activity and microbiome composition.

Materials and methods

Prophylactic potential of PG against bacterial infection was assessed through an in vivo assay employing the nematode worm Caenorhabditis elegans as a model host. Bacterial diversity of the PG samples was revealed through metagenomic analysis.

Results

Duration of fermentation was found to affect biological activity as well as microbiome composition of the PG samples. PG-samples fermented ≥60 min lost their prophylactic potential, and develop anthelmintic activity. Bacterial phyla whose relative abundance was significantly different between the prophylactic and anthelmintic PG samples were Planctomycetota, Proteabacteria, Bacteroidota, Verrucomicrobiota, Patescibacteria, Acidobacteriota, Chloroflexi, Firmicutes and Campilobacterota.

Conclusion

This study validates the prophylactic potential of Panchagavya against bacterial pathogens, and shows that duration of the fermentation time while preparing PG can have profound effect on its biological activities. Biological activities of PG samples seem to have a correlation with their inherent microbial community. Metagenomic profiling can be an effective tool for standardization of PG formulations.

本研究旨在探讨在铜制容器中发酵潘查伽伐雅(PG)制剂的持续时间是否会影响其生物活性和微生物组组成。结果发现发酵时间会影响 PG 样品的生物活性和微生物组组成。发酵≥60 分钟的 PG 样品失去了其预防潜力,并产生了驱虫活性。预防性 PG 样品和驱虫 PG 样品中相对丰度有显著差异的细菌门为 Planctomycetota、Proteabacteria、Bacteroidota、Verrucomicrobiota、Patescibacteria、Acidobacteriota、Chloroflexi、Firmicutes 和 Campilobacterota。PG 样品的生物活性似乎与其固有的微生物群落有关。元基因组分析是实现 PG 配方标准化的有效工具。
{"title":"Duration of fermentation affects microbiome composition and biological activity of an Indian traditional formulation – Panchagavya","authors":"Gemini Gajera ,&nbsp;Snehal Funde ,&nbsp;Hanmanthrao Palep ,&nbsp;Vijay Kothari","doi":"10.1016/j.jaim.2023.100880","DOIUrl":"https://doi.org/10.1016/j.jaim.2023.100880","url":null,"abstract":"<div><h3>Objective</h3><p>This study aimed at investigating whether the duration of fermenting <em>Panchagavya</em> (PG) preparation in copper vessel affects its biological activity and microbiome composition.</p></div><div><h3>Materials and methods</h3><p>Prophylactic potential of PG against bacterial infection was assessed through an <em>in vivo</em> assay employing the nematode worm <em>Caenorhabditis elegans</em> as a model host. Bacterial diversity of the PG samples was revealed through metagenomic analysis.</p></div><div><h3>Results</h3><p>Duration of fermentation was found to affect biological activity as well as microbiome composition of the PG samples. PG-samples fermented ≥60 min lost their prophylactic potential, and develop anthelmintic activity. Bacterial phyla whose relative abundance was significantly different between the prophylactic and anthelmintic PG samples were Planctomycetota, Proteabacteria, Bacteroidota, Verrucomicrobiota, Patescibacteria, Acidobacteriota, Chloroflexi, Firmicutes and Campilobacterota.</p></div><div><h3>Conclusion</h3><p>This study validates the prophylactic potential of <em>Panchagavya</em> against bacterial pathogens, and shows that duration of the fermentation time while preparing PG can have profound effect on its biological activities. Biological activities of PG samples seem to have a correlation with their inherent microbial community. Metagenomic profiling can be an effective tool for standardization of PG formulations.</p></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"15 2","pages":"Article 100880"},"PeriodicalIF":2.4,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0975947623001973/pdfft?md5=724a8b8030c76d6908fe07a69da2ae9f&pid=1-s2.0-S0975947623001973-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140062487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Ayurveda and Integrative Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1